- Home
- NUVL
NUVL
Nuvalent Inc.
as 10-29-2025 4:00pm EST
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 6.5B | IPO Year: | 2021 |
| Target Price: | $121.45 | AVG Volume (30 days): | 498.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $55.53 - $103.69 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Nuvalent Inc. (NUVL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shair Matthew | NUVL | Director | Oct 28 '25 | Sell | $100.27 | 41,609 | $4,172,134.43 | 1,383,044 | |
| Shair Matthew | NUVL | Director | Oct 27 '25 | Sell | $100.23 | 18,391 | $1,843,329.93 | 1,383,044 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Oct 20 '25 | Sell | $94.91 | 5,000 | $474,550.00 | 49,086 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Oct 16 '25 | Sell | $91.47 | 12,376 | $1,134,442.21 | 49,086 | |
| Porter James Richard | NUVL | President and CEO | Oct 16 '25 | Sell | $91.44 | 27,000 | $2,447,020.92 | 249,762 | |
| Miller Deborah Ann | NUVL | Chief Legal Officer | Oct 15 '25 | Sell | $89.98 | 15,624 | $1,405,847.52 | 49,086 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Oct 15 '25 | Sell | $85.57 | 1,683 | $144,014.31 | 61,734 | |
| Pelish Henry E. | NUVL | Chief Scientific Officer | Oct 15 '25 | Sell | $90.04 | 14,205 | $1,279,018.20 | 65,963 | |
| Balcom Alexandra | NUVL | Chief Financial Officer | Oct 14 '25 | Sell | $87.24 | 20,000 | $1,724,015.60 | 61,734 | |
| Pelish Henry E. | NUVL | Chief Scientific Officer | Oct 14 '25 | Sell | $86.16 | 2,433 | $208,698.92 | 65,963 |
Latest Nuvalent Inc. News
NUVL Breaking Stock News: Dive into NUVL Ticker-Specific Updates for Smart Investing
PR Newswire
12 days ago
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
MT Newswires
13 days ago
Nuvalent Insider Sold Shares Worth $1,279,018, According to a Recent SEC Filing
MT Newswires
13 days ago
Nuvalent Insider Sold Shares Worth $2,540,290, According to a Recent SEC Filing
MT Newswires
13 days ago
Nuvalent Insider Sold Shares Worth $2,447,021, According to a Recent SEC Filing
MT Newswires
a month ago
Nuvalent Insider Sold Shares Worth $2,346,256, According to a Recent SEC Filing
MT Newswires
2 months ago
Nuvalent Insider Sold Shares Worth $293,642, According to a Recent SEC Filing
PR Newswire
2 months ago
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
TipRanks
4 months ago
Nuvalent price target raised to $140 from $125 at Leerink
Compare NUVL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVL Nuvalent Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.